You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Novel Small Molecule for the Prevention and Treatment of Diabetic Retinopathy

    SBC: EXCITANT THERAPEUTICS LLC            Topic: NEI

    SUMMARY Diabetic retinopathy (DR) is a leading cause of blindness in the United States. Currently, most treatments for DR are only applicable at the late stage and are invasive. Anti-VEGF (vascular endothelial growth factor) agents have achieved impressive therapeutic effects against DR and neovascularization (NV). However, 40% of patients with DR have inadequate responses to the treatment. Given ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a commercial assay for the rapid and general detection of PFAS in environmental matrices (Phase I)

    SBC: WEAVER LABS LLC            Topic: R

    AbstractPolyfluoro- and perfluoroalkyl substances (PFAS) are a group of highly fluorinated alkanes. Members of this family are known to be persistent and bioaccumulative. PFAS are associated with unfavorable health outcomes in human and animal models. Several public health agencies as well as scientists have published articles that indicate the presence of PFAS in human blood, serum, milk, cord bl ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Crosslinkable Tissue Particles for Regenerating Craniofacial Bone in an Ovine Model

    SBC: Leefa Biotech LLC            Topic: NIDCR

    PROJECT SUMMARY The overall goal of this application is the translation of a new crosslinkable bone void filler that will allow surgeons to better heal patients after craniofacial bone loss. The bone void filler designed is unique in that it can be implanted as a paste then quickly transition to a solid after initiation with blue light. The ability to transition into a solid after placement is uni ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Ophthalmic Product for Corneal Infections and Injuries

    SBC: BIOLYTX PHARMACEUTICALS CORP            Topic: NEI

    Biolytx Pharmaceuticals Corp. is developing a peptide, BP001, derived from the human endogenous host defense protein CAP37, as a novel multi-target ophthalmic product for corneal infections and injuries. The standard-of-care for corneal infections is topical administration of antibiotics that may be accompanied by topical steroids, to limit the destructive effect of the resulting corneal inflammat ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Development of high affinity novel Fluor Mop adsorbent for the rapid removal of perfluorinated chemicals from groundwater

    SBC: WEAVER LABS LLC            Topic: R

    Perfluorinated alkyl substances (PFAS), nicknamed “Forever Chemicals”, are extensively used in industries and firefighting applications as a component of aqueous film forming foams (AFFFs). Because members of this class of chemicals are persistent, they are prevalent in nature and are detected across the globe in water, air, soil, plants, animals, and even in human milk and blood. They are tox ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel Small Molecule for The Prevention and Treatment of Age-Related Macular Degeneration

    SBC: EXCITANT THERAPEUTICS LLC            Topic: NEI

    SUMMARY Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly in the U.S. Wet AMD accounts for up to 90% of vision loss in AMD patients, which is characterized by choroidal neovascularization (CNV). Currently, no cure exists for AMD, and available drug therapies focus on intravitreal injection of anti- vascular endothelial growth factor (VEGF) agents. These anti-V ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Optimizing population health outcomes in diabetic retinopathy through personalized and scalable screening strategies

    SBC: RETINAL CARE INC            Topic: NEI

    Project Summary / Abstract According to the National Eye Institute (NEI), early detection and timely treatment can reduce the risk of severe vision loss from diabetic retinopathy (DR) by 95%. Yet, DR remains the leading cause of blindness among American adults. By 2030, 54.9 million Americans are expected to have diabetes. The prevalence of vision-threatening diabetic retinopathy (VTDR) among peop ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a DCLK1 siRNA Nanoparticle as Targeted Therapy to Treat Pancreatic Cancer

    SBC: COARE HOLDINGS INC            Topic: 102

    Abstract: Pancreatic ductal adenocarcinoma (PDAC) is one of the most devastating human cancers. It is the fourth leading cause of cancer-related deaths in the U.S. annually, with a lt7% 5-year survival rate. Despite FDA-approved therapeutic regimens and marked improvements in medical and surgical care, no significant impact on PDAC patient survival has been achieved. In 2017, some 53,000 Americans ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Disposable, medication-integrated tactile and motion sensor for glaucoma therapy compliance improvement

    SBC: RETINAL CARE INC            Topic: N

    ABSTRACT Glaucoma is the leading cause of irreversible blindness in the world. The number of people with primary open angle glaucoma is expected to exceed 100 million by 2040. The first-line therapy for glaucoma treatment is patient-administered hypotensive medication delivered topically via an eye drop. However, studies have consistently shown that patients rarely adhere to dosing recommendations ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Wearable Transcutaneous Electrical Acustimulation for Gastroparesis

    SBC: TRANSTIMULATION RESEARCH INC            Topic: NCCIH

    Gastroparesis is a common disease defined as delayed gastric emptying with associated symptoms in the absence of mechanical obstructions. It is reported in about 25-30% of patients with functional dyspepsia and affects about 10-20% of general population, including 40% prevalence in type 1 diabetes. Gastroparesis is a refractory disease with a lack of therapeutic options. Common symptoms of gastrop ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government